WillItSurvive
Pharma and healthcare groups · China

BeiGene

beigene.com ↗

Oncology drugmaker behind BRUKINSA, a leukemia drug driving most of its sales.

Defensible for now
Assessed 24 July 2026 · Evidence as of 24 July 2026
Real protection, with named pressure against it.
On the recordSince 24 July 2026 · Checkable from May 2026 · Every call on the record Checkpoint: AbbVie patent litigation ruling expected
The call

BeOne earns most of its money from one drug facing patent suits, while newer therapies still ramp up to spread the risk.

BeiGene makes cancer medicines, with one drug called BRUKINSA bringing in about 75% of all its money and growing fast. The company is protected by patents and regulatory rules that keep competitors out until 2037, but it faces real threats: AbbVie, AstraZeneca, and others sell similar cancer drugs that work in comparable ways, and lawsuits from AbbVie and generic makers could force cheaper copies into the market earlier if BeiGene loses in court. The biggest question is whether BeiGene can launch new cancer drugs from its pipeline soon enough to stop being so dependent on just one medicine, because if BRUKINSA faces legal trouble or China-US tensions disrupt its business, the company's growth could stall.

Why
01
AI pressure: None apparent. AI speeds drug discovery broadly, but it doesn't shortcut clinical trials or patent protection here. Could AI do the core job? Unlikely.
02
Bigger players: AbbVie (Imbruvica, Venclexta). AbbVie's Imbruvica and Venclexta compete directly, and AbbVie is suing over patent rights, with a ruling due May 2026. Could a giant copy it? No, they are blocked.
03
What protects it. U.S. patents protect BRUKINSA until 2037, and a settlement with generic maker MSN blocks early copies.
What would change this call
Outcome of AbbVie v. BeiGene patent litigation (order expected May 2026). Adverse ruling could open earlier competition against BRUKINSA's revenue base.
Zydus ANDA patent suit resolution (filed Feb 2026). Generic entry timeline for BRUKINSA before 2037 protection could shift.
MANGROVE Phase 3 frontline MCL readout and sonrotoclax commercial ramp through 2026. Shows whether revenue is diversifying beyond BRUKINSA's ~75% concentration.
Key numbers
  • FY2025 revenue $5.3B, up 40% year over year (2026-02-26)
  • BRUKINSA sales $3.9B in FY2025, up 49% (2026-02-26)
  • FY2026 revenue guidance $6.2B to $6.4B (2026-02-26)
Named risks
  • BRUKINSA accounts for roughly 75% of total revenue, exposing BeOne to single-drug concentration. Severity: high
  • Active patent litigation with AbbVie and Zydus could open earlier generic or competitor entry. Severity: high
  • US-China geopolitical decoupling could disrupt BeOne's hybrid US/China R&D and commercial model. Severity: medium
  • Insider sold roughly $18.3 million in shares, reported mid-July 2026. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
AbbVielosing toBRUKINSA won ALPINE trial vs Imbruvica; holds ~35% of new US CLL starts, as of 2026-03
AstraZenecacontestingCalquence competes head to head with BRUKINSA in CLL/MCL, no resolved trial as of 2026
Eli Lilly/Loxogaining onJaypirca targets post-BTK relapse patients, encroaching on BeOne's franchise
Nurix TherapeuticscontestingNurix BTK degraders compete against BeOne's own BGB-16673 degrader program
Zydus PharmaceuticalscontestingBeOne sued Zydus Feb 25, 2026 over generic BRUKINSA ANDA filing
Questions people ask
Is BeiGene (now BeOne Medicines) profitable in 2026?
Yes. BeOne Medicines, formerly BeiGene, achieved GAAP net profitability for the first time in FY2025, with total revenue of $5.3 billion, up 40% year over year, reported February 26, 2026.
Who owns BeiGene now that it's renamed BeOne Medicines?
BeOne Medicines has no single corporate parent. It is a publicly traded, triple-listed company on Nasdaq (ONC), Hong Kong (06160), and Shanghai STAR (688235), following its May 27, 2025 redomiciliation from the Cayman Islands to Basel, Switzerland.
Could AI replace BeiGene's drug business?
No. BeOne's revenue comes from regulated, patented prescription cancer drugs like BRUKINSA reimbursed through payers, not from services AI can substitute. AI may cut discovery costs but cannot bypass FDA approvals or patent protection through 2037.
Is BeiGene's flagship drug BRUKINSA protected from generics?
Largely yes. A November 19, 2024 settlement with MSN Pharmaceuticals locks composition-of-matter patent protection until 2037. However, BeOne sued Zydus Pharmaceuticals on February 25, 2026 over a separate generic ANDA filing, so litigation risk remains.
Who is BeiGene's biggest competitor?
AbbVie, via its BTK inhibitor Imbruvica and BCL-2 drug Venclexta, is BeOne's primary rival; BRUKINSA won the ALPINE head-to-head trial and holds roughly 35% of new US CLL starts as of March 2026, per BeOne-linked sources.
Did BeiGene change its name?
Yes. BeiGene completed its rebrand to BeOne Medicines Ltd. on May 27, 2025, along with redomiciliation from the Cayman Islands to Basel, Switzerland, while keeping its Nasdaq listing under the new ticker ONC.
Timeline
  • 2026-07-23Announces $300M US manufacturing expansion at Hopewell, NJ, adding ~120 jobs
  • 2026-05-13FDA grants accelerated approval to Beqalzi (sonrotoclax) for relapsed/refractory MCL
  • 2026-05-12AbbVie v. BeOne patent litigation order issued in N.D. Illinois
  • 2026-02-26Reports FY2025 revenue of $5.3B (+40% YoY), BRUKINSA sales $3.9B (+49% YoY)
  • 2026-02-25BeOne sues Zydus Pharmaceuticals over generic BRUKINSA ANDA filing
  • 2025-05-27Renamed to BeOne Medicines, redomiciled from Cayman Islands to Basel, Switzerland
  • 2025-02-27Reports FY2024 revenue of $3.8B, up 55% YoY
  • 2024-11-19Settles litigation with MSN Pharmaceuticals, locking BRUKINSA patent protection to 2037
Revision history
24 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources